Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolving targets for risk reduction in diabetes.

Gregory M Caputo1, Joel B Braunstein, Roger S Blumenthal

  • 1Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA. gcaputo@psu.edu

Clinical Cardiology
|March 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Exploring automated plasma phospho-tau217 assays for the diagnosis of Down syndrome-related Alzheimer's disease.

Communications medicine·2026
Same author

Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning.

medRxiv : the preprint server for health sciences·2026
Same author

Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adults.

Nature communications·2026
Same author

Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognition.

Brain : a journal of neurology·2026
Same author

Plasma p-tau217 predicts PET-based pathological staging for precision Alzheimer disease assessment.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure.

Clinical cardiology·2026
Same journal

Beyond Rural Versus Urban: Referral Pathways and Structural Heart Programs May Influence Outcomes After Left Atrial Appendage Occlusion.

Clinical cardiology·2026
Same journal

Strauss-Defined LBBB Identifies Patients With Improved Outcomes After CRT-D: A Comparative Cohort Study.

Clinical cardiology·2026
Same journal

Does Serum γKlotho Truly Provide Incremental Prognostic Value Beyond Established Risk Predictors in Multivessel Coronary Artery Disease?

Clinical cardiology·2026
Same journal

Associations of the C-Reactive Protein-Albumin-Lymphocyte Index, Red Cell Distribution Width-Albumin Ratio, and Blood Urea Nitrogen-Albumin Ratio With All-Cause and Cardiovascular Mortality Among Adults With Preclinical Heart Failure.

Clinical cardiology·2026
Same journal

Real-World National Databases Versus Hypothesis-Driven Cohort Studies: A Reply to the Critique on the TURK-HF Registry Design.

Clinical cardiology·2026
See all related articles

Patients with diabetes benefit from lower cholesterol targets (<100 mg/dl) and improved blood pressure control. Pharmacologic therapy is recommended for cardiovascular risk reduction in diabetes management.

Area of Science:

  • Cardiology
  • Endocrinology
  • Public Health

Background:

  • Diabetes mellitus significantly increases macrovascular disease risk.
  • Current guidelines recommend specific targets for low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) in diabetic patients.
  • The impact of glycemic control on macrovascular complications requires ongoing evaluation.

Purpose of the Study:

  • To review current evidence on optimal lipid and blood pressure targets for cardiovascular risk reduction in patients with diabetes.
  • To examine the relationship between blood glucose levels and macrovascular disease risk.
  • To propose healthcare delivery modifications for enhanced diabetes risk management.

Main Methods:

  • Systematic review of recent clinical evidence and observational studies.

Related Experiment Videos

  • Analysis of data pertaining to lipid-lowering therapy, antihypertensive treatment, and glycemic control.
  • Synthesis of findings to inform clinical recommendations and healthcare strategies.

    • Main Results:

    • Evidence supports a target LDL-C of <100 mg/dl for patients with diabetes, with benefits observed even in those with initially lower levels.
    • Lower blood pressure targets below 140/90 mmHg are beneficial, with no evidence supporting a higher threshold for benefit.
    • The review addresses the complex interplay between blood glucose control and macrovascular risk.

    Conclusions:

    • Aggressive management of dyslipidemia and hypertension is crucial for reducing macrovascular complications in diabetes.
    • Pharmacologic interventions are beneficial for cardiovascular risk reduction in diabetic populations.
    • Systematic changes in healthcare delivery are necessary to effectively implement risk reduction strategies for diabetes.